Published on September 18, 2009 at 6:49 AM
BioSante Pharmaceuticals, Inc. (NASDAQ:BPAX) and Cell Genesys, Inc. (NASDAQ:CEGE), today jointly announced that RiskMetrics Group – ISS Governance Services, a leading proxy advisory firm, has recommended that BioSante and Cell Genesys stockholders vote “FOR” the adoption of the merger agreement between BioSante and Cell Genesys at their upcoming respective special meeting of stockholders scheduled to be held on September 30, 2009.
BioSante and Cell Genesys encourage all stockholders to vote their shares promptly by phone, Internet or by mailing their proxy card. The boards of directors of both companies unanimously recommend that stockholders vote “FOR” the adoption of the merger agreement.
BioSante stockholders in need of assistance voting their shares can call BioSante’s proxy solicitor, Laurel Hill Advisory Group, LLC, toll-free at (888) 742-1305. Cell Genesys stockholders in need of assistance voting their shares can call Cell Genesys’s proxy solicitor, Innisfree M&A Incorporated, toll-free at (800) 750-5833.
http://www.biosantepharma.com/
00127265-4b13-4978-8942-d368c13ccf8f|0|.0
Posted in:
Tags: Calcium, Cell, Contraception, Drug Delivery, Estradiol, Estrogen, H1N1, Menopause, Sexual Dysfunction, Swine Flu, Testosterone, Vaccine